Maribel Health, a company that helps health systems design, build and operate technology-enabled home and community clinical care services, has secured $25 million in a Series A funding round led by: General catalyst.
The New Hampshire-based company launched as General Catalyst’s “hatch” program, where a venture capital firm provides resources to start up companies and then partners with them as they grow.
Maribel Health offers clinical workflows, training, technology, operational capabilities and automation for remote clinical care teams as an extension of a health system or ambulatory clinic.
The company also announced a partnership with St. Louis Mercy Health System and New Jersey-based BAYADA Home Health Care, in which Maribel will design, develop and manage hospital programs that will ultimately be the foundation for other home care models.
The funds will be used to accelerate growth with the company’s existing partners, hire new talent and further develop its technology platform.
“Together with our shared vision of providing healthcare, we built Maribel; a technology-enabled operating partner with a mission to work within health systems to integrate advanced home and community care,” Hemant Tanejan, CEO and CEO, General Catalyst. said in the statement.
“Maribel is the latest hatch company to employ the GC build strategy, joining our early company-building successes, namely Livongo, Commure, Kayak and Homeward. We believe that this paradigm shift towards meeting people where they are will improve the quality of care and increase the overall capacity of the healthcare system.”
Dublin-based connected medical device company Fire1 has closed a $25 million funding round led by Andera Partners and Novo Holdings.
The round also included existing investors Gilde Healthcare, Ireland Strategic Investment Fund, New Enterprise Associates, Lightstone Ventures, Gimv, Medtronic and Seventure Partners.
Andera Life Sciences principal Aneta Sotil and Novo Holdings venture capital partner Eric Snyder will join the company’s board of directors.
The company offers an implant that allows remote monitoring of heart failure patients. Fire1 will use the funds to accelerate development of its remote monitoring solution.
ProtaiThe AI-powered drug discovery platform announced that it has raised $12 million in its seed funding, bringing the total amount raised to $20 million.
Existing investors Grove Ventures and Pitango HealthTech participated in the round along with Copenhagen-based Maj Invest Equity Fund.
The Israeli company analyzes protein-level biomarkers using its proteomics AI-based platform to map disease processes to help researchers discover drugs and predict which patients will respond to a given drug.
The company will use the additional funds to build its oncology drug discovery pipeline, grow its activities through pharmaceutical partnerships and expand data collection.
Funds are added to the company $8 million in seed funding received in 2022.
Salim Ismail will present in more detail his HIMSS23 “Summit Keynote: disruptive convergence” during the presentation. It is scheduled for Monday, April 17th from 3:45 – 4:30 CT at the Marriott Marquis Chicago, Level 4, Grand Horizon Ballroom.